Talaris Therapeutics (Nasdaq:TALS) - Cotización, noticias y análisis

Resumen de acción TALS

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States.

TALS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los beneficios han disminuido un 40.8% al año en los últimos 5 años

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Los accionistas han sido diluidos sustancialmente en el último año

Competidores de Talaris Therapeutics, Inc.

Lyell Immunopharma

NasdaqGS:LYEL

US$553.2m

IGM Biosciences

NasdaqGS:IGMS

US$554.2m

Olema Pharmaceuticals

NasdaqGS:OLMA

US$556.5m

Frequency Therapeutics

NasdaqCM:FREQ

US$547.3m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Talaris Therapeutics
Historical stock prices
Current Share Price	US$27.20
52 Week High	US$32.90
52 Week Low	US$8.90
Beta	2.18
1 Month Change	-5.88%
3 Month Change	-11.69%
1 Year Change	91.55%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-83.26%

Noticias y actualizaciones recientes

Recent updates

Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial

Jun 30

Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans

Mar 23

Talaris Therapeutics EPS beats by $0.49

Jun 14

Rentabilidad de los accionistas

	TALS	US Biotechs	Mercado US
7D	-4.9%	0.1%	2.2%
1Y	91.5%	-1.0%	22.8%

Rentabilidad vs. Industria: TALS superó al sector US Biotechs , que obtuvo un rendimiento del -3.7% el año pasado.

Rentabilidad vs. Mercado: TALS superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.

Volatilidad de los precios

Is TALS's price volatile compared to industry and market?
TALS volatility
TALS Average Weekly Movement	5.6%
Biotechs Industry Average Movement	11.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: TALS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de TALS (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1988	84	Mary Fenton	talaristx.com

Resumen de fundamentos de Talaris Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Talaris Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de TALS
Capitalización bursátil	US$553.16m
Beneficios(TTM)	-US$74.77m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-7.4x

Ratio precio-beneficio (PE)

¿Está TALS sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de TALS
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$74.77m
Beneficios	-US$74.77m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-3.68
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado TALS a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción TALS

Recompensas

Análisis de riesgos

Competidores de Talaris Therapeutics, Inc.

NasdaqGS:LYEL

US$553.2m

NasdaqGS:IGMS

US$554.2m

NasdaqGS:OLMA

US$556.5m

NasdaqCM:FREQ

US$547.3m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. (NasdaqGM:TALS) from a group of shareholders in a reverse merger transaction.

New major risk - Shareholder dilution

New minor risk - Market cap size

Talaris Therapeutics, Inc. Announces Special Dividend

Talaris Therapeutics, Inc. Announces Special Dividend

Price target increased by 39% to US$12.50

Recent updates

Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. (NasdaqGM:TALS) from a group of shareholders in a reverse merger transaction.

New major risk - Shareholder dilution

New minor risk - Market cap size

Talaris Therapeutics, Inc. Announces Special Dividend

Talaris Therapeutics, Inc. Announces Special Dividend

Price target increased by 39% to US$12.50

Tourmaline Bio, Inc. entered into a definitive agreement to acquire Talaris Therapeutics, Inc. (NasdaqGM:TALS) from shareholders in a reverse merger transaction.

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Founder recently sold US$80k worth of stock

Founder notifies of intention to sell stock

Talaris Therapeutics, Inc. Appoints Mary Kay Fenton as President

Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?

Price target decreased by 17% to US$7.50

Founder recently sold US$319k worth of stock

Price target decreased by 17% to US$7.50

Price target increased by 11% to US$10.00

Founder notifies of intention to sell stock

Price target decreased by 12% to US$8.40

Talaris Therapeutics, Inc. Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan

Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?

Price target decreased to US$9.60

Talaris Therapeutics, Inc. Presents Data on Mechanisms of Fcr001 Activity to Induce Immune Tolerance

Price target increased to US$16.75

Talaris Therapeutics Provides Update on Freedom-1 Phase 3 Clinical Trial

We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Talaris drops 24% after patient death in late-stage trial for lead asset

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Member of Scientific Advisory Board notifies of intention to sell stock

Talaris Therapeutics GAAP EPS of -$0.44

President recently bought US$167k worth of stock

Independent Chairman recently bought US$500k worth of stock

We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Price target decreased to US$15.25

Talaris Therapeutics Provides Freedom-1 Phase 3 Clinical Update

Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial

Talaris Therapeutics, Inc.(NasdaqGM:TALS) dropped from Russell 2000 Growth Index

Talaris Therapeutics Presents Additional Phase 2 Data and Analyses At American Transplant Congress 2022

Talaris Therapeutics, Inc. Announces Board Changes

Talaris Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

Talaris Therapeutics, Inc Shares New Data on COVID-19 Outcomes Among Living Donor Kidney Transplant Patients Treated in its Phase 2 Trial of Investigational Cell Therapy Product FCR001 (NCT00497926)

Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans

Talaris Therapeutics, Inc. Presents High-Resolution Analysis of HLS Mismatching in Phase 2 Trial in Living Donor Kidney Transplant

Talaris Therapeutics EPS beats by $0.49

Talaris Therapeutics, Inc. has completed an IPO in the amount of $150.025 million.

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Talaris Therapeutics, Inc.

0.0x

-7.4x

Beneficios e Ingresos